AB-423 is primarily utilized in the development of antiviral therapies. It is being studied for its potential to inhibit the replication of hepatitis B virus (HBV), making it a promising candidate for treating chronic HBV infections. Researchers are focusing on its ability to target specific viral proteins, thereby reducing viral load and improving patient outcomes. Its application in clinical trials aims to assess its efficacy and safety as part of combination therapies or as a standalone treatment. This compound represents a significant step forward in addressing unmet medical needs in hepatitis B treatment.